DE60009477T2 - Injizierbare naltrexon mikrosphären zusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum - Google Patents

Injizierbare naltrexon mikrosphären zusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum Download PDF

Info

Publication number
DE60009477T2
DE60009477T2 DE60009477T DE60009477T DE60009477T2 DE 60009477 T2 DE60009477 T2 DE 60009477T2 DE 60009477 T DE60009477 T DE 60009477T DE 60009477 T DE60009477 T DE 60009477T DE 60009477 T2 DE60009477 T2 DE 60009477T2
Authority
DE
Germany
Prior art keywords
naltrexone
poly
microspheres
lactide
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60009477T
Other languages
German (de)
English (en)
Other versions
DE60009477D1 (de
Inventor
R. Thomas TICE
K. Jay STAAS
M. Teresa FERRELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surmodics SMP Inc
Original Assignee
SOUTHERN RES INST BIRMINGHAM
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOUTHERN RES INST BIRMINGHAM, Southern Research Institute filed Critical SOUTHERN RES INST BIRMINGHAM
Application granted granted Critical
Publication of DE60009477D1 publication Critical patent/DE60009477D1/de
Publication of DE60009477T2 publication Critical patent/DE60009477T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60009477T 1999-04-09 2000-04-08 Injizierbare naltrexon mikrosphären zusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum Expired - Lifetime DE60009477T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12847799P 1999-04-09 1999-04-09
US128477P 1999-04-09
PCT/US2000/009438 WO2000061147A1 (en) 1999-04-09 2000-04-08 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol

Publications (2)

Publication Number Publication Date
DE60009477D1 DE60009477D1 (de) 2004-05-06
DE60009477T2 true DE60009477T2 (de) 2005-02-24

Family

ID=22435553

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009477T Expired - Lifetime DE60009477T2 (de) 1999-04-09 2000-04-08 Injizierbare naltrexon mikrosphären zusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum

Country Status (25)

Country Link
US (1) US6306425B1 (enExample)
EP (1) EP1171132B1 (enExample)
JP (2) JP4995371B2 (enExample)
KR (1) KR100621261B1 (enExample)
CN (1) CN1210031C (enExample)
AT (1) ATE262906T1 (enExample)
AU (1) AU780852B2 (enExample)
BR (1) BR0009639A (enExample)
CA (1) CA2369302C (enExample)
CZ (1) CZ20013636A3 (enExample)
DE (1) DE60009477T2 (enExample)
DK (1) DK1171132T3 (enExample)
EA (1) EA004734B1 (enExample)
ES (1) ES2218147T3 (enExample)
HK (1) HK1047245B (enExample)
HU (1) HUP0200838A3 (enExample)
IL (2) IL145802A0 (enExample)
MX (1) MXPA01010185A (enExample)
NO (1) NO328647B1 (enExample)
NZ (1) NZ515359A (enExample)
PL (1) PL196930B1 (enExample)
PT (1) PT1171132E (enExample)
TR (1) TR200102880T2 (enExample)
UA (1) UA79921C2 (enExample)
WO (1) WO2000061147A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU2001223396A1 (en) * 2000-02-01 2001-08-14 Disetronic Licensing Ag Container and device for administering a substance
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
DE60223254T2 (de) 2001-07-06 2008-08-14 Penwest Pharmaceuticals Co. Verzögert freisetzende formulierungen von oxymorphon
JP2005515966A (ja) 2001-07-06 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7053134B2 (en) 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en) 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
MXPA05009803A (es) * 2003-03-13 2006-04-18 Cheryl M Burgess Metodos para administrar un material en un paciente para realce dermico.
EP1628664A4 (en) * 2003-06-04 2008-11-05 Alkermes Inc POLYMORPHIC FORMS OF NALTREXONE
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050031713A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP3A4 sensitive patients
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
EP1667659A1 (en) * 2003-09-30 2006-06-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
LT2351555T (lt) * 2004-02-23 2016-12-27 Euro-Celtique S.A. Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7919499B2 (en) 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
CN1872063B (zh) * 2005-06-03 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 纳美芬或其盐的长效注射用微球或组合物及其制备方法
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
EP1810714A1 (de) * 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Heroin und Naloxon zur Drogensubstitution
RU2310449C1 (ru) * 2006-05-17 2007-11-20 Руслан Геннадьевич Нервалев Способ лечения опиоидной и/или алкогольной зависимости
WO2009051824A2 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
RU2010129907A (ru) 2007-12-17 2012-01-27 Лабофарм Инк. (CA) Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
WO2015020240A1 (ko) 2013-08-06 2015-02-12 동국제약 주식회사 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물
WO2016013993A1 (en) * 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
WO2020080806A1 (en) 2018-10-15 2020-04-23 Chong Kun Dang Pharmaceutical Corp. Injectable long-acting naltrexone microparticle compositions
GR1009871B (el) * 2019-07-30 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει μικροσφαιριδια ναλτρεξονης και μεθοδος παρασκευης αυτου
US20210059943A1 (en) * 2019-09-04 2021-03-04 Buffalo Pacific LLC Systems and methods addressing multiple aspects to provide a comprehensive recovery program for addictions, chronic conditions and diseases
CA3208374A1 (en) * 2021-03-09 2022-09-15 Ju Hee Kim Sustained formulation for prevention or treatment of autoimmune disease containing naltrexone and method using same
CA3236690A1 (en) * 2021-11-18 2023-05-25 Ju Hee Kim Sustained-release injectable composition containing naltrexone and method for preparing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4981696A (en) 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
DE3710175A1 (de) 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
FR2618674B1 (fr) 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4902515A (en) 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
DE69024953T3 (de) 1989-05-04 2005-01-27 Southern Research Institute, Birmingham Einkapselungsverfahren
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AU7582498A (en) * 1997-05-20 1998-12-11 Yale University Substance dependence treatment using opiate antagonists and serotonin compounds
JPH11269094A (ja) * 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途

Also Published As

Publication number Publication date
EP1171132B1 (en) 2004-03-31
JP2002541202A (ja) 2002-12-03
NO20014896D0 (no) 2001-10-08
EA200101062A1 (ru) 2002-04-25
BR0009639A (pt) 2002-02-05
KR100621261B1 (ko) 2006-09-13
PL350548A1 (en) 2002-12-16
CA2369302A1 (en) 2000-10-19
WO2000061147A1 (en) 2000-10-19
NO20014896L (no) 2001-12-07
CN1354664A (zh) 2002-06-19
KR20020011975A (ko) 2002-02-09
EA004734B1 (ru) 2004-08-26
TR200102880T2 (tr) 2002-03-21
PT1171132E (pt) 2004-07-30
UA79921C2 (en) 2007-08-10
IL145802A (en) 2009-02-11
JP2010031036A (ja) 2010-02-12
ES2218147T3 (es) 2004-11-16
HK1047245B (zh) 2006-03-03
JP4995371B2 (ja) 2012-08-08
HUP0200838A2 (hu) 2002-07-29
MXPA01010185A (es) 2003-07-21
DE60009477D1 (de) 2004-05-06
DK1171132T3 (da) 2004-07-12
NZ515359A (en) 2002-10-25
CZ20013636A3 (cs) 2002-03-13
HK1047245A1 (en) 2003-02-14
HUP0200838A3 (en) 2005-07-28
EP1171132A1 (en) 2002-01-16
IL145802A0 (en) 2002-07-25
US6306425B1 (en) 2001-10-23
CA2369302C (en) 2007-09-25
CN1210031C (zh) 2005-07-13
AU4220300A (en) 2000-11-14
AU780852B2 (en) 2005-04-21
ATE262906T1 (de) 2004-04-15
PL196930B1 (pl) 2008-02-29
NO328647B1 (no) 2010-04-19

Similar Documents

Publication Publication Date Title
DE60009477T2 (de) Injizierbare naltrexon mikrosphären zusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
DE60015370T2 (de) Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
DE69523295T2 (de) Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung
DE69030095T2 (de) Vorrichtung zum verabreichen von medikamenten auf schleimhautgewebe
DE69327542T2 (de) Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
DE69107026T2 (de) Injizierbare galenische retardzubereitung.
DE60315939T2 (de) Pharmazeutische zusammensetzung enthaltend ein androgen
US20200085732A1 (en) Prolonged Release of Local Anesthetics Using Microparticles and Surgery Applications
DE2601207B2 (de) Verfahren zur Herstellung einer flüssigen pharmazeutischen Zubereitung mit gesteuertem Arzneimittelabgabevermögen
DE3782117T2 (de) Verkapselung von trh bzw. dessen analoga.
US20050031668A1 (en) Implantable polymeric device for sustained release of nalmefene
DE2940146C2 (enExample)
DE69614419T2 (de) Transdermale Formulierung eines Mittels muscarinischer Wirkung
EP4585210A1 (en) Compound slow-release implant of naltrexone and risperidone, preparation method therefor, and use thereof
DE69627365T2 (de) Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten
DE2821949A1 (de) Arzneimittel mit depotwirkung
DE4244265C2 (de) Verwendung von Paf-Antagonisten gegen die neue Ausbildung von Paf-Bindungsstellen auf endothelialen Zellen zur Behandlung oder Vorbeugung des Hyperinsulinismus
EP2863887B1 (de) Emulsion zur pharmazeutischen anwendung und verfahren zu deren herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BROOKWOOD PHARMACEUTICALS INC., BIRMINGHAM, ALA.,

8328 Change in the person/name/address of the agent

Representative=s name: WEICKMANN & WEICKMANN, 81679 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: HOEFER & PARTNER, 81543 MUENCHEN